"Hyperlipidemias" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions with excess LIPIDS in the blood.
| Descriptor ID |
D006949
|
| MeSH Number(s) |
C18.452.584.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hyperlipidemias".
Below are MeSH descriptors whose meaning is more specific than "Hyperlipidemias".
This graph shows the total number of publications written about "Hyperlipidemias" by people in this website by year, and whether "Hyperlipidemias" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 1 | 3 |
| 1997 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 3 | 0 | 3 |
| 2001 | 2 | 3 | 5 |
| 2002 | 6 | 1 | 7 |
| 2003 | 3 | 2 | 5 |
| 2004 | 6 | 3 | 9 |
| 2005 | 7 | 3 | 10 |
| 2006 | 3 | 0 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 3 | 4 |
| 2011 | 0 | 1 | 1 |
| 2012 | 2 | 1 | 3 |
| 2013 | 4 | 3 | 7 |
| 2014 | 2 | 3 | 5 |
| 2015 | 5 | 3 | 8 |
| 2016 | 2 | 2 | 4 |
| 2017 | 2 | 2 | 4 |
| 2018 | 4 | 1 | 5 |
| 2019 | 4 | 2 | 6 |
| 2020 | 4 | 2 | 6 |
| 2021 | 3 | 1 | 4 |
| 2022 | 10 | 0 | 10 |
| 2023 | 4 | 0 | 4 |
| 2024 | 3 | 0 | 3 |
| 2025 | 2 | 2 | 4 |
| 2026 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hyperlipidemias" by people in Profiles.
-
Impact of Hyperlipidemia on Osseointegration and Peri-implant Diseases. J Dent Res. 2026 07; 105(8):972-981.
-
Cardiometabolic Outcomes after Surgical Remission of Endogenous Hypercortisolism: A Prospective Cohort Study. J Clin Endocrinol Metab. 2026 May 19; 111(6):1613-1627.
-
Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial. Nat Med. 2026 Apr; 32(4):1432-1443.
-
Vascular Risk Factors and 1-Year Cognitive Change Among Individuals With Traumatic Brain Injury. JAMA Netw Open. 2025 Aug 01; 8(8):e2525719.
-
Treatment of severe hyperlipidemia and associated cardiovascular outcomes: Data from a large healthcare system. J Clin Lipidol. 2025 Sep-Oct; 19(5):1256-1263.
-
Global Effect of Cardiovascular Risk Factors on Lifetime Estimates. N Engl J Med. 2025 Jul 10; 393(2):125-138.
-
Foamy monocytes and atherogenesis in mice with combined hyperlipidemia and effects of antisense knockdown of apoCIII. J Lipid Res. 2025 04; 66(4):100763.
-
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. N Engl J Med. 2024 09 12; 391(10):913-925.
-
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. N Engl J Med. 2024 09 12; 391(10):899-912.
-
Association of Atherosclerotic Cardiovascular Disease, Hypertension, Diabetes, and Hyperlipidemia With Gulf War Illness Among Gulf War Veterans. J Am Heart Assoc. 2023 10 03; 12(19):e029575.